Sign inJoin waitlistJoin the waitlist

Swaminathan Iyer

Physician · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Miami/Jackson Health System
2000–2003
Medical Education and Research
Wayne State University
1997–2000
All India Institute of Medical Sciences
1996
Doctor of Medicine
1992–1996

Research

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet · 2019 · 613 citations
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Journal of Clinical Oncology · 2012 · 564 citations
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
Journal of Clinical Oncology · 2010 · 459 citations

Sairah Ahmed
39 papers
Jason Westin
38 papers
Loretta Nastoupil
37 papers
Ranjit Nair
37 papers
Christopher Flowers
36 papers
Sattva Neelapu
34 papers
Paolo Strati
32 papers
Luis Fayad
31 papers
RS
Raphael Steiner
28 papers · 19 as a fellow
Jeffrey Medeiros
26 papers
Hun Lee
24 papers · 3 as a resident
RM
Roberto Miranda
21 papers

Grants

Mays Cancer Center at UT San Antonio Health Science Center
National Cancer Institute · P30
Project lead · $78K · University of Texas Hlth Science Center
2009–2014

Clinical trials

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
Principal investigator · Active not recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2017–2027
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Principal investigator · Unknown · Phase 1, Phase 2
OncoVista, Inc.
2008–2010
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Principal investigator · Completed · Phase 1
Innate Pharma
2007–2011
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Site PI · Recruiting · Phase 2
March Biosciences Inc
2025–2029